Indication
Papillary Thyroid Cancer
14 clinical trials
19 products
1 drug
Clinical trial
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2024-12-15
Product
LOXO-292Product
EntrectinibClinical trial
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
TY-1091Clinical trial
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET AlterationsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
PralsetinibClinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-21
Product
CM-24 and NivolumabProduct
CM-24Clinical trial
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationStatus:
Product
SelpercatinibClinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Product
AMXT1501Product
DFMOProduct
68-Gallium DotatateClinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-02
Product
TrametinibProduct
DabrafenibDrug
SpartalizumabClinical trial
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2024-06-30
Product
RadioiodineClinical trial
Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAYStatus: Recruiting, Estimated PCD: 2027-10-30
Product
GenotypingClinical trial
Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility andStatus: Completed, Estimated PCD: 2019-12-31
Product
EMI-137Clinical trial
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer PatientsStatus: Recruiting, Estimated PCD: 2023-12-31
Product
ImatinibClinical trial
Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of PatientsStatus: Recruiting, Estimated PCD: 2026-01-01